Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that. Regeneron and Sanofi (NYSE: SNY) reported updated data for cemiplimab in skin cancer earlier today and based on that data, the two companies have begun a rolling application for FDA approval. Will this drug move the needle for these companies?
Cemiplimab belongs to a class of drugs called PD-1 inhibitors that help disable a cancer's ability to escape detection by the immune system.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Regeneron Pharmaceuticals Inc. Aktie
1.080,0 €
0,56 %
Überwältigendes Buy-Interesse bei Regeneron Pharmaceuticals Inc., mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Ein positives, aber moderates Potenzial für Regeneron Pharmaceuticals Inc. mit einem Kursziel von 1091 € im Vergleich zu 1080.0 €.
